Buchumschlag

Personalized medicine in allergic asthma: at the crossroads of allergen immunotherapy and “biologicals”

Major allergic disease can be viewed as clinical syndromes rather than discrete disease entities. Emerging evidence indicates that allergic asthma includes several disease phenotypes. Immunological deviation towards high T helper cell type 2 (Th2) cytokine levels has been demonstrated for a subgroup...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Fritzsching, Benedikt (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 17 February 2017
In: Frontiers in Pediatrics
Year: 2017, Jahrgang: 5, Pages: 1-4
ISSN:2296-2360
DOI:10.3389/fped.2017.00031
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.3389/fped.2017.00031
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/articles/10.3389/fped.2017.00031/full
Volltext
Verfasserangaben:Benedikt Fritzsching

MARC

LEADER 00000caa a2200000 c 4500
001 1575487640
003 DE-627
005 20230427042910.0
007 cr uuu---uuuuu
008 180524s2017 xx |||||o 00| ||eng c
024 7 |a 10.3389/fped.2017.00031  |2 doi 
035 |a (DE-627)1575487640 
035 |a (DE-576)505487640 
035 |a (DE-599)BSZ505487640 
035 |a (OCoLC)1341010049 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Fritzsching, Benedikt  |d 1974-  |e VerfasserIn  |0 (DE-588)124900518  |0 (DE-627)367769778  |0 (DE-576)294559000  |4 aut 
245 1 0 |a Personalized medicine in allergic asthma  |b at the crossroads of allergen immunotherapy and “biologicals”  |c Benedikt Fritzsching 
264 1 |c 17 February 2017 
300 |a 4 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 24.05.2018 
520 |a Major allergic disease can be viewed as clinical syndromes rather than discrete disease entities. Emerging evidence indicates that allergic asthma includes several disease phenotypes. Immunological deviation towards high T helper cell type 2 (Th2) cytokine levels has been demonstrated for a subgroup of pediatric asthma patients and now several novel monoclonal antibodies have been approved for treatment of this subgroup as a stratified approach of "personalized" medicine in allergy. Introduction of component-based IgE testing before allergen immunotherapy (AIT), i.e. testing for IgE-crossreactivity before initiation of AIT, has also brought stratified medicine into allergy therapy. Improved responder criteria, which identify treatment-responders previous to therapy, might foster this stratification and even individualized AIT might have an impact for tailor-made therapy in the future. Furthermore, combining antibody-based treatment with AIT could help to establish more rapid AIT protocols even for allergens with a high risk of anaphylactic reactions. Efforts to advance such "personalized" medicine in pediatric allergy might be challenged by several issues including: High costs for the healthcare system, increasing complexity of allergy therapy, the need for physician allergy expertise and furthermore ethical considerations and data safety issues. 
650 4 |a allergen immunotherapy 
650 4 |a allergy 
650 4 |a Asthma 
650 4 |a biologicals 
650 4 |a monoclonal antibodies 
650 4 |a personalized medicine 
650 4 |a Stratified Medicine 
773 0 8 |i Enthalten in  |t Frontiers in Pediatrics  |d Lausanne : Frontiers Media, 2013  |g 5(2017), Artikel-ID 31, Seite 1-4  |h Online-Ressource  |w (DE-627)742738744  |w (DE-600)2711999-3  |w (DE-576)381569756  |x 2296-2360  |7 nnas  |a Personalized medicine in allergic asthma at the crossroads of allergen immunotherapy and “biologicals” 
773 1 8 |g volume:5  |g year:2017  |g elocationid:31  |g pages:1-4  |g extent:4  |a Personalized medicine in allergic asthma at the crossroads of allergen immunotherapy and “biologicals” 
856 4 0 |u http://dx.doi.org/10.3389/fped.2017.00031  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.frontiersin.org/articles/10.3389/fped.2017.00031/full  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20180524 
993 |a Article 
994 |a 2017 
998 |g 124900518  |a Fritzsching, Benedikt  |m 124900518:Fritzsching, Benedikt  |d 910000  |d 911460  |d 50000  |e 910000PF124900518  |e 911460PF124900518  |e 50000PF124900518  |k 0/910000/  |k 1/910000/911460/  |k 0/50000/  |p 1  |x j  |y j 
999 |a KXP-PPN1575487640  |e 301013228X 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"recId":"1575487640","note":["Gesehen am 24.05.2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"given":"Benedikt","family":"Fritzsching","role":"aut","roleDisplay":"VerfasserIn","display":"Fritzsching, Benedikt"}],"title":[{"subtitle":"at the crossroads of allergen immunotherapy and “biologicals”","title":"Personalized medicine in allergic asthma","title_sort":"Personalized medicine in allergic asthma"}],"relHost":[{"title":[{"title":"Frontiers in Pediatrics","title_sort":"Frontiers in Pediatrics"}],"titleAlt":[{"title":"FPED"}],"part":{"pages":"1-4","year":"2017","extent":"4","volume":"5","text":"5(2017), Artikel-ID 31, Seite 1-4"},"pubHistory":["2013 -"],"recId":"742738744","language":["eng"],"note":["Gesehen am 04.06.20"],"disp":"Personalized medicine in allergic asthma at the crossroads of allergen immunotherapy and “biologicals”Frontiers in Pediatrics","type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"zdb":["2711999-3"],"eki":["742738744"],"issn":["2296-2360"]},"origin":[{"dateIssuedDisp":"2013-","publisher":"Frontiers Media","dateIssuedKey":"2013","publisherPlace":"Lausanne"}],"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"4 S."}],"name":{"displayForm":["Benedikt Fritzsching"]},"id":{"doi":["10.3389/fped.2017.00031"],"eki":["1575487640"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"17 February 2017"}]} 
SRT |a FRITZSCHINPERSONALIZ1720 

Ähnliche Einträge